Skip to main content
Have a personal or library account? Click to login
Do we use methylation of NFATC1 and FOS genes as a biomarker for postmenopausal osteoporosis? Cover

Do we use methylation of NFATC1 and FOS genes as a biomarker for postmenopausal osteoporosis?

Balkan Journal of Medical Genetics
Volume 23 (2020): Issue 2 (November 2020)
By:  and    
Open Access
|Mar 2021
Figures & tables

Figures & Tables

Figure 1

Methylated NFATC1 patients. The NFATC1 unmethylated control was orange, the methylated control was red. Patients 41 and 34 were methylated.

Figure 2

Methylated FOS patients. The FOS unmethylated control was purple, the methylated control was red. Patients 8 and 19 were methylated.

Table 1

Methylation status of NFATC1 and FOS in post- and premenopausal women.

ParametersPostmenopausal n (%)Premenopausal n (%)p Value
NFATC1 methylated11 (31.4)19 (63.3)0.010
NFATC1 unmethylated24 (68.8)11 (36.7)
FOS methylated6 (17.1)5 (16.7)>0.050
FOS unmethylated29 (82.9)25 (83.3)
DOI: https://doi.org/10.2478/bjmg-2020-0021 | Journal eISSN: 2199-5761 (formerly 1311-0160) | Journal ISSN: 1311-0160
Journal RSS Feed
Language: English
Page range: 35 - 40
Published on: Mar 23, 2021
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Keywords:
FOS,
NFATC1,
Methylation sensitive-high resolution melting (MS-HRM),
Methylation,
Postmenopause,
Premenopause
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2021 R Kalkan, O Tosun, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 23 (2020): Issue 2 (November 2020)
Previous article
Next article